Acarix heart failure algorithms showed strong sensitivity and fewer false positives than NT-proBNP, but larger external validation is still required.
Coredio’s AI heart failure platform may bring hemodynamic insight into home care. See why FDA breakthrough status matters now.
A pig-heart trial is no longer just a scientific leap. United Therapeutics now faces the harder test of safety, scale, and regulation.
ATTR-CM treatment is shifting earlier. Alnylam must now prove AMVUTTRA can win clinician trust beyond trial subgroups.
Heart failure care needs faster decongestion without kidney harm. Reprieve’s FASTR data now face the pivotal trial test.
Heart failure care needs fewer hospital stays. Lasix ONYU now tests whether Europe is ready for at-home subcutaneous diuresis.
Pulnovo Medical raised $100 million with Medtronic backing. Read what it means for PADN, pulmonary hypertension, heart failure, and device markets.
Lupin Limited has launched generic dapagliflozin in the United States. Read what it means for Farxiga, pricing pressure, and market access.
Roivios Ltd., a clinical-stage medical device developer focused on kidney health, has reported promising results from its first-in-human trial of the JuxtaFlow Renal Assist Device. This investigational system applies controlled negative pressure to the renal pelvis to enhance urine output and sodium excretion in patients with diuretic-resistant cardiorenal syndrome and acute decompensated heart failure. While
Roivios Ltd., a clinical-stage medical device developer, has announced encouraging results from its first-in-human study of the JuxtaFlow Renal Assist Device, a technology designed to support fluid removal and renal function in patients with diuretic-resistant cardiorenal syndrome and acute decompensated heart failure. The results, published in the ASAIO Journal, showed that JuxtaFlow significantly improved both